Table. Laboratory test results for a patient who had type 1 diabetes mellitus associated with nivolumab after a second SARS-CoV-2 vaccination, Japan*.
| Laboratory test | Value |
|---|---|
| Venous blood gas analysis | |
| pH | 7.36 |
| pCO2, mm Hg | 41.1 |
| Bicarbonate, mmol/L | 22.6 |
| Anion gap, mmol/L |
10.0 |
| Biochemical | |
| Creatinine, mg/dL | 0.84 |
| Glomerular filtration rate, mL/min/1.73 m2 | 79.0 |
| Amylase, U/L | 59.0 |
| Lipase, U/L |
26.0 |
| Diabetes-related tests | |
| Plasma glucose, mg/dL | 665 |
| HbA1c, % | 8.0 |
| Acetoacetate, μmol/L | 1,936 |
| 3-hydroxybutyric acid, μmol/L | 2,813 |
| Fasting CPR, ng/mL | 0.13 |
| 24-h CPR, μg/day† | 5.74/3.82 |
| GAD antibody, U/mL | <5.0 |
| IA-2 antibody, U/mL | <0.4 |
| ZnT8 antibody, U/mL |
<10 |
| Glucagon load test | |
| Fasting CPR, ng/mL | 0.09 |
| After 6 min CPR, ng/mL | 0.12 |
| Delta CPR, ng/mL |
0.03 |
| DNA typing | |
| HLA-DRB1*11:01-DQB1*03:01:01 | NA |
| HLA-DRB1*13:02:01-DQB1*06:04:01 | NA |
*CPR, C-peptide immunoreactivity; GAD, glutamic acid decarboxylase; HbA1c, glycated hemoglobin; HLA, human leukocyte antigen; IA-2, insulinoma-associated antigen 2; NA, not applicable; ZnT8, zinc transporter 8. †The 24-h CPR was measured twice for this patient because values can fluctuate greatly for patients who have diabetes.